Department of Nephrology, Akron Nephrology Associates/Cleveland Clinic Akron General, Akron, Ohio, USA.
Department of Nephrology, Akron Children's Hospital, Akron, Ohio, USA.
Blood Purif. 2022;51(3):199-212. doi: 10.1159/000514940. Epub 2021 Jun 15.
The recent worldwide pandemic of COVID-19 has been a serious, multidimensional problem that has left a detrimental worldwide impact on individuals of all ages and several organ systems. The typical manifestation of kidney involvement is acute kidney injury (AKI); however, there is a lack of consensus data regarding AKI epidemiology in COVID-19. This systematic literature review aims to bridge this knowledge gap.
DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: MEDLINE and Cochrane library were systematically searched for the literature related to AKI in COVID-19 patients of all ages. MedRxIV was searched for relevant unpublished manuscripts. Two reviewers independently assessed the literature on the incidence of AKI and mortality, extracting the need for kidney replacement therapy (KRT).
Sixty studies (n = 43,871 patients) were included in this review. The pooled incidence of AKI among COVID-19 patients was 19.45% (95% confidence intervals [95% CI]: 14.63-24.77%), while the pooled incidence of AKI COVID-19 patients requiring KRT was 39.04% (16.38-64.57%). The pooled proportion of COVID+ patients was significantly lower at 8.83% (5.64% to 12/66%). The overall mortality of COVID-19 patients was calculated to be 17.71% (95% CI: 11.49-24.93%), while the mortality among patients with AKI was higher at 54.24% (95% CI: 44.70-63.63%).
This comprehensive systematic review summarizes the available literature pertaining to AKI epidemiology in COVID-19 patients and highlights the incidence, associated mortality, and the need for KRT in this susceptible population.
COVID-19 全球大流行是一个严重的多维问题,对各个年龄段和多个器官系统的个体都产生了有害的全球影响。肾脏受累的典型表现是急性肾损伤(AKI);然而,关于 COVID-19 中 AKI 的流行病学数据尚未达成共识。本系统文献综述旨在弥补这一知识空白。
设计、设置、参与者和测量方法:系统地检索了 MEDLINE 和 Cochrane 图书馆中与 COVID-19 患者 AKI 相关的文献。检索了 MedRxIV 中相关的未发表手稿。两名审查员独立评估了 AKI 发生率和死亡率的文献,提取了需要肾脏替代治疗(KRT)的情况。
本综述纳入了 60 项研究(n = 43871 例患者)。COVID-19 患者中 AKI 的总发生率为 19.45%(95%置信区间[95%CI]:14.63-24.77%),而需要 KRT 的 COVID-19 患者中 AKI 的发生率为 39.04%(16.38-64.57%)。COVID+患者的总比例明显较低,为 8.83%(5.64%至 12/66%)。COVID-19 患者的总体死亡率计算为 17.71%(95%CI:11.49-24.93%),而 AKI 患者的死亡率更高,为 54.24%(95%CI:44.70-63.63%)。
本全面系统综述总结了 COVID-19 患者 AKI 流行病学的现有文献,强调了这一易感人群中 AKI 的发生率、相关死亡率以及对 KRT 的需求。